The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a more substantial reduc